Oxford Vaccine Approved

In the next few months,
UK
Cases, + 53,135
Deaths, + 414

ChAdOx1

Three weeks for good level of immunity

After this people were not hospitalised

One dose can prevent serious disease

Day 22 to 3 months = 70% to 80%

Three billion doses of the vaccine

30 supply agreements and partner networks

Medicines and Healthcare products Regulatory Agency (MHRA)

Has approved two full doses of the Oxford-AstraZeneca vaccine

Not enough clear data to approve the half-dose, full-dose idea

First doses, Monday, 4th January

Pfizer

21 days is not the minimum gap, get more people protected quicker

Doctors can decide to give to pregnant and breast feeding women

People with allergies can also be considered

Joint Committee on Vaccination and Immunisation

Give as many people as possible their first dose of vaccine

Give as many vulnerable people some protection from Covid-19

Second dose, 4 to 12 weeks

Second dose, longer term protection.

Oxford already working on flexibility


Oxford/AstraZeneca Vaccine

MHRA, Medicines and Healthcare Products Regulatory Agency

Fast-track rolling review of the vaccine since November

Enters stage 4 on approval

Pre-orders

EU, 400 million doses

UK, 100 million

US, 300 million

China, 200 million

Japan, 120 million

Brazil, 100 million

Mexico, 77 million

Chile, 14,4 million

Indonesia, 100 million

Australia, 33.6 million

Egypt 30 million

Argentina 32 million

Ecuador 5 million

Canada 20 million

Argentina and Mexico to produce for Latin America

Vaccines alliance for poorer countries, 300 million

COVAX, 170 million

Three billion doses in 2021

Cost

£2

Transport / storage

Fridge temperatures

Lasts six months when refrigerated at 38–46°F (2–8°C)


Efficacy

Pascal Soriot, winning formula

62% 70% 90% 100%

Strong response in older adults

Manufacturing

Keele, UK

Belgium

India, Serum Institute, 1 billion doses

Melbourne, Australia

Thailand, South East Asia

Netherlands and Germany

Across Europe

Shenzhen, China

US

Albuquerque, New Mexico

Maryland

Russia

Mexico


UK, 100 million

Four million ready to go

Fifteen million ready to put into vials

Mass rollout starts 4th January

One million people per week

Mass rollout

Important that no screening is required

Reactogenicity does not appear to be affected by the presences of antibodies to coronavirus.

US

Mr. Biden, 100 million shots in first 100 days

Published evidence base

AZ press release

https://www.astrazeneca.com/media-cen...

Oxford vaccine, home site

https://www.ovg.ox.ac.uk

The Oxford Coronavirus Site

https://www.research.ox.ac.uk/Area/co...

The Jenner Institute

https://www.jenner.ac.uk